Site Search

SEC Filings Details

Investors & Media

Form 4

02/11/2025

Statement of Changes in Beneficial Ownership

PDF Format Download (opens in new window)
Excel Format Download (opens in new window)

Contact Us

Sonya Weigle
Chief People and
Investor Relations Officer
Marinus Pharmaceuticals, Inc.

sweigle@marinuspharma.com

Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.

investors@marinuspharma.com

Quick Links

SEC Filings
Investor FAQs

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Marinus Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Marinus Pharmaceuticals to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options *

News

Events & Presentations

Quarterly Reports

Annual Reports

SEC Filings

End of Day Stock Quote

Unsubscribe